HD Immune GmbH Foundation and Publication of Latest Pre-Clinical Data
HD Immune GmbH (HDI), a privately held biotechnology company developing novel antibody treatments for Huntington’s Disease, announces commencement of operations by its two founders Dr. Stefan Bartl and Dr. Lionel Wightman.
- HD Immune GmbH (HDI), a privately held biotechnology company developing novel antibody treatments for Huntington’s Disease, announces commencement of operations by its two founders Dr. Stefan Bartl and Dr. Lionel Wightman.
- HDI has also closed a pre-seed financing round with an Austrian Business Angel and awarded an Austria Wirtschafts Service (AWS) pre-seed Grant.
- HD Immune is developing an antibody to target the mutated protein and remove it from the body.
- Based on these results, HD Immune intends to further advance the development of a human therapeutic antibody to reduce the symptoms of the disease in the patient.